NextCell Pharma AB
Business description not yet wired for this issuer.
Business. NextCell Pharma AB (NXTCL.ST) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Sweden and primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NextCell Pharma AB (NXTCL.ST) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Sweden and primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not available.
NextCell Pharma AB is a biotechnology company focused on the development of cell-based therapies for the treatment of autoimmune diseases and cancer.
NextCell Pharma AB is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.
NextCell Pharma AB has a total equity of 50,598,500 SEK and no debt, resulting in a debt-to-equity ratio of 0.0. The company's current ratio is 5.16, indicating strong short-term liquidity. However, the company's operating cash flow is negative at -50,899,170 SEK, and capital expenditures are also negative at -4,965,930 SEK, suggesting ongoing investment in operations.
The company's profitability is negative, with a return on equity of -1.0066 and a return on assets of -0.7969. These figures are below the industry norms for biotechnology companies, which typically require high R&D investment and have long development cycles before achieving profitability.
NextCell Pharma AB's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide geographic revenue breakdowns, but it is primarily focused on the European market, with operations in Sweden.
The company's revenue for the latest period was 13,700,470 SEK, which is slightly above the mean analyst estimate of 14,000,000 SEK. However, the company's net income is negative at -50,933,640 SEK, and the mean EPS estimate is -0.40 SEK, indicating continued losses.
The risk assessment for NextCell Pharma AB indicates a low dilution risk, with no significant dilution sources identified in the latest filings. However, the company's liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.
Recent events include the company's continued focus on its lead candidate, NCL-1001, for the treatment of type 1 diabetes. The company has also been working on its pipeline of cell-based therapies for other autoimmune diseases and cancer. No major regulatory or legal issues have been reported in the latest filings.
- NextCell Pharma AB has strong short-term liquidity but is experiencing negative operating cash flow. - The company's profitability is negative, with a return on equity of -1.0066 and a return on assets of -0.7969. - Revenue is concentrated in a single business segment, with no geographic revenue breakdown provided. - The company's revenue is slightly above analyst estimates, but it continues to report losses. - The risk assessment indicates low dilution risk but an inability to assess liquidity risk due to data limitations.
- NextCell Pharma AB (NXTCL.ST) is a biotechnology and medical research company engaged in healthcare diagnostics.
- The firm is headquartered in Sweden and primarily listed on the Nasdaq Stockholm exchange.
- Specific details regarding operating segments and geographic revenue mix are not available.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,40 |
| Revenue | —no estimate | —no estimate | 14,0M SEK |
| Operating income | —no estimate | —no estimate | -49,8M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- NextCell Pharma AB Market data — financials · 2026-05-28
- NextCell Pharma AB Market data — analyst estimates · 2026-05-28